Why did Certara (CERT) stock move recently?

On 8/25/2026, Certara moved +3.2% — No specific company catalyst identified for the 3.2% gain; Certara moved with broader market/sector trends following recent institutional buying interest and post-earnings activity. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Certara (CERT) overvalued or fairly valued?

MarketChacha shows Certara's valuation in context — a forward P/E of about 20.3, a price-to-book of about 1.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Certara's revenue?

Certara reported revenue of $418.8M for FY2025, with net profit of $-1.6M, per official filings.

What is the share price of Certara (CERT)?

Certara last traded at $7.94 (-2.3% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Certara

CERT · NYSE · Healthcare · United States

Snapshot

TickerCERT

ExchangeNYSE

SectorHealthcare

IndustryHealth Information Services

CountryUnited States

Employees1,515

HeadquartersRadnor, United States

Websitewww.certara.com

Filings tracked18

About Certara

Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Who owns it

Insiders2.7%
Institutions97.3%
Public & other0.0%

328 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.34%
Deerfield Management Company, L.P4.93%
Haveli Investment Management LLC4.85%
Jefferies Financial Group Inc.4.65%
Vanguard Portfolio Management LLC4.63%
Dimensional Fund Advisors LP3.95%
Vanguard Capital Management LLC3.46%
State Street Corporation3.16%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of -0.2% is on the low side — the business earns a modest return on shareholder capital.

Net margin trend-15.6% → -0.4%

Margin has expanded by about 15.2 points — the business is getting more profitable.

Return on equity-0.2%

Latest ROE of -0.2% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $94.5M · EPS 0.09

Est. earnings growth +3.2%

Next fiscal year

Rev $389.6M · EPS 0.39

Est. earnings growth +14.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$418.8M

Net margin

-0.4%

ROE

-0.2%

Revenue CAGR (2y)

+8.7%

EPS (FY2025)

-0.01

Net profit (FY2025)

$-1.6M

Ask MarketChacha about CERT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
No specific company catalyst identified for the 3.2% gain; Certara moved with broader market/sector trends following recent institutional buying interest and post-earnings activity.
· confidence: low
Aug 4, 2026
Certara stock fell after reporting Q2 2026 results that missed consensus estimates on both revenue ($93.3M vs ~$98M expected) and EPS ($0.08 vs $0.09), alongside a net loss of $6.1M and modest 1% YoY revenue growth with services revenue declining, despite reaffirming full-year guidance and expanding its share repurchase program.
source 1 ↗source 2 ↗source 3 ↗· confidence: high
Jul 27, 2026
No company-specific catalyst identified in today's credible coverage or filings; the shares rose alongside broader market or sector moves.
· confidence: low
Jul 24, 2026
Certara shares rose amid ongoing positive sentiment and coverage around its mid-July NVIDIA BioNeMo AI partnership for accelerating drug development, with no new company-specific catalyst reported today.
source 1 ↗source 2 ↗source 3 ↗· confidence: medium
Jul 23, 2026
Certara shares rose with the broader market and biotech sector; no company-specific news or filing explains the move.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$418.8M	$-1.6M	-0.01	-0.4%	-0.2%
FY2024	$385.1M	$-12.1M	-0.08	-3.1%	-1.1%
FY2023	$354.3M	$-55.4M	-0.35	-15.6%	-5.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$93.3M	$-55.3M	-0.36	-59.3%
2026Q1	$106.9M	$-8.8M	-0.06	-8.2%
2025Q3	$104.6M	$1.5M	0.01	1.5%
2025Q2	$92.4M	$-2.0M	-0.01	-2.1%
2025Q1	$106.0M	$4.7M	0.03	4.5%
2024Q3	$94.8M	$-1.4M	-0.01	-1.4%
2024Q2	$93.3M	$-12.6M	-0.08	-13.5%
2024Q1	$96.7M	$-4.7M	-0.03	-4.8%
2023Q3	$85.6M	$-49.0M	-0.31	-57.2%
2023Q2	$90.5M	$4.7M	0.03	5.2%
2023Q1	$90.3M	$1.4M	0.01	1.5%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Reg FD disclosure
SEC8/7/2026material
8-K — Executive/director change
SEC8/4/2026material
8-K — Results of operations, Exhibits
SEC8/4/2026material
10-Q filing
SEC8/4/2026
8-K — Executive/director change, Exhibits
SEC6/17/2026material
8-K — Shareholder vote results
SEC5/15/2026material
8-K — Results of operations, Other events, Exhibits
SEC5/11/2026material
10-Q filing
SEC5/11/2026
8-K — Material agreement, Exhibits
SEC4/22/2026material
8-K — Executive/director change
SEC3/31/2026material
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026

2025

8-K — Executive/director change, Exhibits
SEC12/11/2025material
8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Material agreement, Material financial obligation, Exhibits
SEC10/16/2025material
8-K — Results of operations, Exhibits
SEC8/6/2025material
10-Q filing
SEC8/6/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.